Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response

NCT00694096 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Cancer

Interventions

DRUG: Sunitinib

Sponsor

University of Utah

Collaborators

[object Object]